蛋白水解酶前体抑制剂可抑制胃癌肿瘤干细胞干性和侵袭性。
Inhibition of proprotein convertases activity results in repressed stemness and invasiveness of cancer stem cells in gastric cancer.
机构信息
BoRdeaux Institute of onCology (BRIC), INSERM U1312, Univ. Bordeaux, 33000, Bordeaux, France.
Vivoptic Platform, CNRS, INSERM TBM-Core UAR3427 US5, Univ. Bordeaux, 33000, Bordeaux, France.
出版信息
Gastric Cancer. 2024 Mar;27(2):292-307. doi: 10.1007/s10120-023-01462-6. Epub 2024 Jan 27.
BACKGROUND
Gastric cancer (GC), the fourth leading cause of cancer-related death worldwide, with most deaths caused by advanced and metastatic disease, has limited curative options. Here, we revealed the importance of proprotein convertases (PCs) in the malignant and metastatic potential of GC cells through the regulation of the YAP/TAZ/TEAD pathway and epithelial-to-mesenchymal transition (EMT) in cancer stem cells (CSC).
METHODS
The general PCs inhibitor, decanoyl-RVKR-chloromethyl-ketone (CMK), was used to repress PCs activity in CSCs of various GC cell lines. Their tumorigenic properties, drug resistance, YAP/TAZ/TEAD pathway activity, and invasive properties were then investigated in vitro, and their metastatic properties were explored in a mouse xenograft model. The prognostic value of PCs in GC patients was also explored in molecular databases of GC.
RESULTS
Inhibition of PCs activity in CSCs in all GC cell lines reduced tumorsphere formation and growth, drug efflux, EMT phenotype, and invasive properties that are associated with repressed YAP/TAZ/TEAD pathway activity in vitro. In vivo, PCs' inhibition in GC cells reduced their metastatic spread. Molecular analysis of tumors from GC patients has highlighted the prognostic value of PCs.
CONCLUSIONS
PCs are overexpressed in GC and associated with poor prognosis. PCs are involved in the malignant and metastatic potential of CSCs via the regulation of EMT, the YAP/TAZ/TEAD oncogenic pathway, and their stemness and invasive properties. Their repression represents a new strategy to target CSCs and impair metastatic spreading in GC.
背景
胃癌(GC)是全球第四大癌症相关死亡原因,大多数死亡是由晚期和转移性疾病引起的,其治疗方法有限。在这里,我们通过调节 YAP/TAZ/TEAD 通路和癌症干细胞(CSC)中的上皮间质转化(EMT),揭示了前蛋白转化酶(PCs)在 GC 细胞的恶性和转移潜能中的重要性。
方法
使用通用 PCs 抑制剂癸酰基-RVKR-氯甲基酮(CMK)抑制各种 GC 细胞系 CSC 中的 PCs 活性。然后在体外研究它们的致瘤特性、耐药性、YAP/TAZ/TEAD 通路活性和侵袭特性,并在小鼠异种移植模型中研究它们的转移特性。还在 GC 患者的分子数据库中探索了 PCs 在 GC 患者中的预后价值。
结果
在所有 GC 细胞系的 CSC 中抑制 PCs 活性可减少肿瘤球形成和生长、药物外排、EMT 表型和侵袭特性,这与体外 YAP/TAZ/TEAD 通路活性受到抑制有关。在体内,GC 细胞中 PCs 的抑制减少了其转移扩散。对 GC 患者肿瘤的分子分析突出了 PCs 的预后价值。
结论
GC 中 PCs 过表达与预后不良有关。PCs 通过调节 EMT、YAP/TAZ/TEAD 致癌通路及其干性和侵袭特性,参与 CSCs 的恶性和转移潜能。抑制它们代表了一种针对 CSCs 并削弱 GC 转移扩散的新策略。